Product comparison
LOY-001 vs. LOY-003: large-dog longevity programs compared
Compare LOY-001 and LOY-003 by intended age, weight, dosage form, biological target, and regulatory evidence without confusing development claims with approval.
Direct answer
LOY-001 and LOY-003 are separate Loyal drug programs intended for large or giant dogs. Loyal describes LOY-001 as a long-acting injection for dogs age 7 or older weighing at least 40 pounds, and LOY-003 as a daily pill for dogs age 5 or older weighing at least 60 pounds. Neither should be confused with LOY-002 or treated as approved based on a technical milestone.
How the programs differ
The most visible difference is dosage form: LOY-001 is described as a veterinarian-prescribed long-acting injection, while LOY-003 is described as a daily prescription pill. The intended development populations also differ in minimum age and weight.
Those thresholds come from the developer's current public description. They are not final prescribing criteria. Final eligibility, if either product is approved, would come from the approved label and a veterinarian's examination.
- LOY-001: intended for age 7+ and at least 40 lb; long-acting injection.
- LOY-003: intended for age 5+ and at least 60 lb; daily pill.
- LOY-002: a different senior-dog metabolic program, intended for age 10+ and at least 14 lb.
Why large dogs are studied separately
Large body size within domestic dogs is associated with shorter average lifespan. Peer-reviewed population studies support the size-lifespan relationship, but breed averages cannot predict an individual's lifespan.
Loyal says LOY-001 and LOY-003 target IGF-1 signaling, which the company associates with the lifespan difference between large and small dogs. That biological rationale must still be separated from measured clinical outcomes.
What an RXE milestone means
Loyal reports that LOY-001 received a reasonable-expectation-of-effectiveness technical-section complete letter in 2023. FDA's conditional pathway uses this preliminary effectiveness standard, which is not the substantial-evidence standard for full approval.
A milestone for one program does not transfer to another. LOY-001 evidence cannot automatically validate LOY-003, LOY-002, a supplement, or an off-label protocol.
Questions that remain
Owners still need program-specific safety data, manufacturing review, an approval decision, a final label, price, monitoring requirements, and outcome results. Until those exist, a comparison should describe development programs—not rank products or recommend one.
A useful future comparison must keep the denominator visible: how many dogs were screened, enrolled, completed follow-up, stopped treatment, experienced an adverse event, and contributed to each outcome. It should also report absolute effects and uncertainty rather than only relative changes. Without that information, confident product rankings would be marketing disguised as analysis.
Frequently asked questions
Which is better, LOY-001 or LOY-003?
There is not enough public approved-label and outcome evidence to rank them. They also use different dosage forms and intended populations.
Are either available from veterinarians?
The sponsor pages reviewed describe them as drugs in development. Confirm any future availability directly with FDA records and a veterinarian.
Why does dog size matter?
Population research consistently finds shorter average lifespan in larger dogs, but size is only one factor and does not predict one dog's outcome.
Primary sources and limitations
Supports: Sponsor-reported intended populations, dosage form, development status, and the three major technical requirements described for LOY-002.
Limit: This is the developer's own product page, not independent confirmation of lifespan extension or an FDA approval listing.
Supports: The legal meaning of conditional approval, the reasonable-expectation-of-effectiveness standard, annual renewals, and the prohibition on extra-label use.
Limit: This explains the pathway. It is not a product-specific approval record for LOY-002.
Supports: Large population evidence that longevity varies materially across breed, body size, sex, and skull-shape groups.
Limit: Population estimates do not predict one dog's lifespan and should not be converted into treatment claims.
Supports: Evidence that body size and genetic diversity are important confounders in canine lifespan comparisons.
Limit: Observational breed-level associations do not establish that a particular intervention extends life.
Continue the evidence trail
Educational information only. This page does not diagnose, prescribe, or replace a veterinarian who knows your dog.